Literature DB >> 2073098

Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

N Rastogi1, K S Goh.   

Abstract

In the present work, we investigated whether resistance to isoniazid (INH) of organisms belonging to the Mycobacterium avium complex was caused by the bacterial cell envelope, with the cell wall and the outer layer acting as an exclusion barrier. We observed that this exclusion barrier was most efficient in excluding the hydrophilic drug INH, as this drug could not penetrate a wall matrix formed of various polymethylated lipidic or amphipathic substances. Two main strategies were proposed for circumventing this drug resistance: (i) synthesis of amphipathic derivatives of otherwise highly hydrophilic drugs and (ii) inhibition of synthesis of the bacterial outer layer. The purpose of this work was to demonstrate that attaching a palmitic acid side chain to INH rendered it growth inhibitory against M. avium complex bacteria and that the concomitant use of this amphipathic INH derivative with m-fluorophenylalanine (an inhibitor of mycoside C biosynthesis which causes the disruption of the bacterial outer layer) resulted in further enhancement of its activity, leading to a bactericidal effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073098      PMCID: PMC171999          DOI: 10.1128/AAC.34.11.2061

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Effect of temperature on the rate of the transparent to opaque colony type transition in Mycobacterium avium.

Authors:  C L Woodley; H L David
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Uptake of selected antibacterial agents in Mycobacterium avium.

Authors:  H L David; S Clavel-Seres; F Clement; K S Goh
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-07

3.  Basis for lack of drug susceptibility of atypical mycobacteria.

Authors:  H L David
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

4.  Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 5.  Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex.

Authors:  L S Young; C B Inderlied; O G Berlin; M S Gottlieb
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

6.  Structure of the cell envelope of Mycobacterium avium.

Authors:  H L David; N Rastogi; S Clavel-Sérès; F Clément; M F Thorel
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-04

7.  Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

Authors:  N Rastogi; C Frehel; A Ryter; H Ohayon; M Lesourd; H L David
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

8.  Utilization of palmitic acid by Mycobacterium avium.

Authors:  C McCarthy
Journal:  Infect Immun       Date:  1971-09       Impact factor: 3.441

9.  Medical therapy of Mycobacterium avium-intracellulare pulmonary disease.

Authors:  E T Etzkorn; S Aldarondo; C K McAllister; J Matthews; A J Ognibene
Journal:  Am Rev Respir Dis       Date:  1986-09

10.  Variation in isoniazid susceptibility of Mycobacterium avium during the cell cycle.

Authors:  C M McCarthy
Journal:  Am Rev Respir Dis       Date:  1981-04
View more
  8 in total

1.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh; J P De Sousa
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

3.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

4.  In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

5.  Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.

Authors:  N Rastogi; K S Goh; E L Wright; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

6.  Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

7.  Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Authors:  Michael J Hearn; Michael H Cynamon; Michaeline F Chen; Rebecca Coppins; Jessica Davis; Helen Joo-On Kang; Abigail Noble; Becky Tu-Sekine; Marianne S Terrot; Daniella Trombino; Minh Thai; Eleanor R Webster; Rebecca Wilson
Journal:  Eur J Med Chem       Date:  2009-05-21       Impact factor: 6.514

Review 8.  Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives.

Authors:  A Rattan; A Kalia; N Ahmad
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.